

- **Name:** Keun-Wook Lee, M.D. & Ph.D.
- **Current Position & Affiliation:** Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital
- **Country:** Republic of Korea

• Educational Background:

Institution and Location	Degree	Year	Field of study
Seoul National University College of Medicine	M.D.	1992-1998	General medicine
Seoul National University, Graduate School	M.S.	2002~2004	Internal medicine
Seoul National University, Graduate School	Ph.D.	2004~2007	Molecular oncology

• Professional Experience:

- Medical Oncology (Focused on gastric and colorectal cancers)
- Cancer clinical trials including early phase clinical trials & Translational research

• Professional Organizations:

Institution and location	Position	Year-year
Seoul National University Hospital	Resident	2000~2004
Seoul National University Hospital	Clinical Fellowship	2004~2005
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital	Clinical Professor	2005~2013.
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University College of Medicine / Seoul National University Bundang Hospital	Associate Professor	2013.9.~2018.2.
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University College of Medicine / Seoul National University Bundang Hospital	Professor	2018.3.~Present
Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital	Chief	2016.7.~2020.6.
Clinical Trial Center, Seoul National University Bundang Hospital	Director	2020.4.~Present
Comprehensive Cancer Center, Seoul National University Bundang Hospital	Director	2024.7.~Present
Korean Cancer Association	Secretary General	2024.7.~Present
Korean Cancer Study Group (Stomach Cancer Committee)	Chairperson	2025.3.~Present

• Main Scientific Publications:

1	Enzastaurin, a protein kinase C β inhibitor, suppresses signaling through the ribosomal S6 kinase and Bad pathways and induces apoptosis in human gastric cancer cells	200803	Cancer Res	Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi H, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ
2	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial	201201	Lancet	Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Szízen F, Noh SH; for the CLASSIC trial investigators
3	Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer	201204	Ann Oncol	Chang HJ, Lee KW, Kim JH, Bang SM, Kim YJ, Kim DW, Kang SB, Lee JS

4	Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy	201208	Ann Oncol	NJ Kim, C Park, DJ Park, HH. Kim, S Kim, YJ. Kim, JH Kim, JS Lee, YJ Bang, SI. Khwarg, H Choung, MJ. Lee & KW Lee
5	Significant Association of oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients.	201501	Clin Cancer Res	Lee KW , Lee SS, Kim SB, Sohn BH, Lee HS, Jnag HJ, Park YY, Kopetz S, Kim SS, Oh SC, Lee JS
6	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer.	201612	Clin Cancer Res	Lee KW , Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Choeng JH, Cho JY, Lim JY, etc.
7	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial	201712	Lancet	Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW , Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
8	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).	201901	Oncologist	Lee KW , Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, Oh SC, Chung JS, Song HS, Kim JW, Jeong SJ, Cho JY
9	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)	202101	Gastric Cancer	Lee KW , Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators.
10	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab+/-Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study	202208	Clin Cancer Res	Lee KW , Van Cutsem E, Bang YJ, Fuchs CS, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Chao J, Wainberg ZA, Cao ZA, Aurora-Garg D, Kobie J, Cristescu R, Bhagia P, Shah S, Tabernero J, Shitara K, Wyrwicz L
11	Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study	202211	Lancet Oncol	Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hirtre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW .
12	Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study	202212	Lancet Oncol	Meric-Bemstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW .
13	A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)	202310	Cancer Res Treat	Lee KW , Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS.
14	Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes for prediction of prognosis in resected colon cancer	202311	NPJ Precis Oncol	Lim Y, Choi S, Oh HJ, Kim C, Song S, Kim S, Song H, Park S, Kim JW, Kim JW, Kim JH, Kang M, Kang SB, Kim DW, Oh HK, Lee HS, Lee KW
15	Liquid Biopsy: An Emerging Diagnostic, Prognostic, and Predictive Tool in Gastric Cancer	202401	J Gastric Cancer	Han HS, Lee KW
16	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer	202402	ESMO Open	Shitara K, Fleitas T, Kawakami H, Curigliano G, Narita Y, Wang F, Wardhani SO, Basade M, Rha SY,....., Lee KW , Krishna V,....., Cervantes A, Ishioka C, Smyth E
17	Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial	202405	BMJ	Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, Zimina AV, Bai Y, Shi J, Lee KW ,....., Xu RH; RATIONALE-305 Investigators.
18	Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer	202507	Gastric Cancer	Kim JW, Kyung DS, Ko WY, Kim HP, Hwang SH, Kim KJ, Lee JH, Seo J, Kang M, Jung EH, Suh KJ, Kim SH, Kim JW, Kim YJ, Kim JH, Lee KW
19	DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.	202507	Nat Commun	Lee KW , Mahalingam D, Shim BY, Kim IH, Oh DY, Uronis H, Sym SJ, Sonbol M, Almhanna K, Tejani MA, Kang B, Kagey MH, Stilian M, Jia C, Sirard CA, Ajani JA, Klempner SJ.
20	Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study	202507	Lancet Oncol	Elimova E, Ajani J, Burris H, Denlinger CS, Iqbal S, Kang YK, Kim JH, Lee KW , Lin B, Mehta R, Oh DY, Rha SY, Seol YM, Yang L, Ozog MA, Garfin PM, Ku G